← All trials
NCT04713709
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Mar 30, 2021
- Completion date
- Oct 10, 2021
- First posted
- Jan 19, 2021
- Last posted
- Oct 13, 2021
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nasus PharmaLead sponsor
- Pharma MedicaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.